{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:54Z","timestamp":1787246694918,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"LEO Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01818-7","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:16:04Z","timestamp":1781280964000},"page":"3979-3999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment"],"prefix":"10.1007","volume":"16","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Bin Sawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-6525","authenticated-orcid":false,"given":"Nisha C.","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Balu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Maslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9a","family":"Libchaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"5","key":"1818_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/DER.0000000000000659","volume":"32","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Agner T, Bissonnette R, Cohen DE, Simpson E, et\u00a0al. Chronic hand eczema guidelines from an expert panel of the International Eczema Council. Dermatitis. 2021;32(5):319\u201326.","journal-title":"Dermatitis."},{"issue":"4","key":"1818_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/cod.14477","volume":"90","author":"E Borg","year":"2024","unstructured":"Borg E, Munro D, Thoning H. The management of chronic hand eczema: A retrospective patient record review. Contact Dermatitis. 2024;90(4):365\u201371.","journal-title":"Contact Dermatitis."},{"issue":"5","key":"1818_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et\u00a0al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378.","journal-title":"Contact Dermatitis."},{"issue":"5","key":"1818_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/ced\/llae522","volume":"50","author":"B Halioua","year":"2025","unstructured":"Halioua B, Skayem C, Merhand S, BenHayoun Y, Taieb C, Richard MA. Chronic hand eczema in France: Occupational impact and work absenteeism. Clin Exp Dermatol. 2025;50(5):1044\u20136.","journal-title":"Clin Exp Dermatol."},{"issue":"7","key":"1818_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jdv.19055","volume":"37","author":"H Ronsch","year":"2023","unstructured":"Ronsch H, Schiffers F, Ofenloch R, Weisshaar E, Buse AS, Hansen A, et\u00a0al. Chronic hand eczema in Europe: Patient experiences and perspectives (CHEPEP) in qualitative interviews. J Eur Acad Dermatol Venereol. 2023;37(7):1396\u2013405.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1818_CR6","doi-asserted-by":"publisher","first-page":"1075672","DOI":"10.3389\/fmed.2023.1075672","volume":"10","author":"VS Vasiliou","year":"2023","unstructured":"Vasiliou VS, Russell H, Cockayne S, Coelho GLH, Thompson AR. A network analysis of psychological flexibility, coping, and stigma in dermatology patients. Front Med (Lausanne). 2023;10:1075672.","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"1818_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cod.12130","volume":"70","author":"PA Cortesi","year":"2014","unstructured":"Cortesi PA, Scalone L, Belisari A, Bonamonte D, Cannavo SP, Cristaudo A, et\u00a0al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158\u201368.","journal-title":"Contact Dermatitis."},{"issue":"6","key":"1818_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/cod.12973","volume":"78","author":"SE Marron","year":"2018","unstructured":"Marron SE, Tomas-Aragones L, Navarro-Lopez J, Gieler U, Kupfer J, Dalgard FJ, et\u00a0al. The psychosocial burden of hand eczema: Data from a European dermatological multicentre study. Contact Dermatitis. 2018;78(6):406\u201312.","journal-title":"Contact Dermatitis."},{"issue":"6","key":"1818_CR9","doi-asserted-by":"publisher","DOI":"10.25251\/fv5g8d65","volume":"9","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Balu S, Bin Sawad A, Apol ED, Schneider S, Maslin D, et\u00a0al. Prevalence of self-reported physician diagnosis of chronic hand eczema in adults: A cross-sectional study of more than 10,000 participants in the general population\u2014results from the CHECK study in the United States. J of Skin. 2025;9(6):s676.","journal-title":"J of Skin."},{"issue":"Suppl 4","key":"1818_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jdv.14319","volume":"31","author":"JH Alfonso","year":"2017","unstructured":"Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, et\u00a0al. Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe\u2014position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol. 2017;31(Suppl 4):31\u201343.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1818_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: Successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag."},{"key":"1818_CR12","unstructured":"ANZUPGO\u00ae (delgocitinib) cream prescribing information. Madison, NJ: LEO Pharma Inc; July 2025."},{"key":"1818_CR13","unstructured":"National Eczema Association. FDA approves the first treatment for moderate-to-severe chronic hand eczema. 2025 July 25 [cited 2025 November 14]. Available from: https:\/\/nationaleczema.org\/blog\/breaking-news-fda-approves-the-first-treatment-for-moderate-to-severe-chronic-hand-eczema\/."},{"issue":"1","key":"1818_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jaad.2025.08.081","volume":"94","author":"M Zirwas","year":"2026","unstructured":"Zirwas M, Fowler JF Jr, Tsianakas A, Devani AR, Halden P, Lai Z, et\u00a0al. Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study. J Am Acad Dermatol. 2026;94(1):32\u201340.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"1818_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Sygula E, et\u00a0al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90(6):1190\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"1818_CR16","unstructured":"Ehst B, Warren. R B, Hong HC, Silvestre JF, Lee DH, Balakirski G, et\u00a0al. Tralokinumab is effective and well-tolerated in adults with atopic dermatitis with moderate-to-severe hand involvement who are candidates for systemic therapy: Week 16 results from the phase 3b ADHAND trial. Georg Rajka International Symposium on Atopic Dermatitis (ISAD) Annual Meeting; October 24\u201326, 2025; Melbourne, Australia."},{"issue":"4","key":"1818_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bjd\/ljad156","volume":"189","author":"AN Voorberg","year":"2023","unstructured":"Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: A randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023;189(4):400\u20139.","journal-title":"Br J Dermatol."},{"key":"1818_CR18","unstructured":"ClinicalTrials.gov. NCT06283550. Efficacy, safety, and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema refractory to corticosteroid therapy. 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06283550."},{"issue":"2","key":"1818_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","volume":"89","author":"PA Jimenez","year":"2023","unstructured":"Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, et\u00a0al. Oral spleen tyrosine kinase\/Janus kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023;89(2):235\u201342.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"1818_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et\u00a0al. Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health."},{"issue":"1","key":"1818_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/09546634.2016.1177161","volume":"28","author":"AB Hauber","year":"2017","unstructured":"Hauber AB, Mohamed AF, Gonzalez JM, Otteson Fairchild A, Zelt SC, Graff O. Benefit-risk tradeoff preferences for chronic hand eczema treatments. J Dermatolog Treat. 2017;28(1):40\u20136.","journal-title":"J Dermatolog Treat."},{"key":"1818_CR22","unstructured":"Armstrong AW, Bin Sawad A, Hazra NC, Balu S, Maslin D, Gauthier-Loiselle M, et\u00a0al. P0284. Patient perspectives in moderate-to-severe chronic hand eczema: Understanding patient experience and factors influencing treatment preference through in-depth qualitative patient interviews in the US. Presented at: European Academy of Dermatology and Venereology (EADV) Congress; September 17\u201320, 2025; Paris, France."},{"key":"1818_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med."},{"key":"1818_CR24","doi-asserted-by":"crossref","unstructured":"Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: Results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8\u201312, 2024; San Diego, CA.","DOI":"10.1093\/bjd\/ljae266.034"},{"issue":"1","key":"1818_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","volume":"93","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Molin S, Bissonnette R, Worm M, Cr\u00e9py M-N, Stingeni L, et\u00a0al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93(1):95\u2013103.","journal-title":"J Am Acad Dermatol."},{"issue":"10451","key":"1818_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et\u00a0al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): Results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet."},{"issue":"4","key":"1818_CR27","first-page":"1","volume":"3","author":"HD Smith","year":"2024","unstructured":"Smith HD, Lally JS, Moy A, Ryan-Wolf J, De Benedetto A. Topical ruxolitinib 1.5% (JAK1\/JAK2 inhibitor) improves clinical and patient-reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open-label trial. JEADV Clin Pract. 2024;3(4):1\u201311.","journal-title":"JEADV Clin Pract."},{"key":"1818_CR28","unstructured":"DUPIXENT\u00ae (dupilumab) injection prescribing information. Tarrytown, NY: Regeneron Pharmaceuticals Inc; June 2025."},{"key":"1818_CR29","unstructured":"ZORYVE\u00ae (roflumilast) cream prescribing information. Westlake Village, CA: Arcutis Biotherapeutics Inc; October 2025."},{"key":"1818_CR30","unstructured":"OPZELURA\u00ae (ruxolitinib) cream prescribing information. Wilmington, DE: Incyte Corporation; September 2025."},{"issue":"4","key":"1818_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et\u00a0al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health."},{"issue":"5","key":"1818_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"key":"1818_CR33","unstructured":"ChoiceMetrics. Ngene 1.1.1 User Manual & Reference Guide. Australia; 2012."},{"issue":"3","key":"1818_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient. 2019;12(3):287\u201395.","journal-title":"Patient."},{"issue":"3","key":"1818_CR35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1080\/09546634.2020.1832185","volume":"33","author":"M Boeri","year":"2022","unstructured":"Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, Di Bonaventura M. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatolog Treat. 2022;33(3):1449\u201358.","journal-title":"J Dermatolog Treat."},{"issue":"1","key":"1818_CR36","doi-asserted-by":"publisher","first-page":"2417966","DOI":"10.1080\/09546634.2024.2417966","volume":"35","author":"N Durno","year":"2024","unstructured":"Durno N, Arija P, Pantiri K, Heisen M, Boeri M, Paris J, et\u00a0al. Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: A discrete choice experiment in the United Kingdom and Germany. J Dermatolog Treat. 2024;35(1):2417966.","journal-title":"J Dermatolog Treat."},{"issue":"1","key":"1818_CR37","doi-asserted-by":"publisher","first-page":"2345739","DOI":"10.1080\/09546634.2024.2345739","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Guerin A, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, et\u00a0al. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: A discrete choice experiment. J Dermatolog Treat. 2024;35(1):2345739.","journal-title":"J Dermatolog Treat."},{"issue":"1","key":"1818_CR38","doi-asserted-by":"publisher","first-page":"2215356","DOI":"10.1080\/09546634.2023.2215356","volume":"34","author":"K Myers","year":"2023","unstructured":"Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Treat. 2023;34(1):2215356.","journal-title":"J Dermatolog Treat."},{"issue":"8","key":"1818_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058799","volume":"12","author":"C Thomas","year":"2022","unstructured":"Thomas C, Raibouaa A, Wollenberg A, Capron JP, Krucien N, Karn H, et\u00a0al. Patient preferences for atopic dermatitis medications in the UK, France and Spain: A discrete choice experiment. BMJ Open. 2022;12(8):e058799.","journal-title":"BMJ Open."},{"key":"1818_CR40","volume":"9","author":"B Halioua","year":"2026","unstructured":"Halioua B, T\u00e9tart F, Leleu C, Reguiai Z, Misery L, Giordano F, et\u00a0al. A practical approach to the management of chronic hand eczema: Expert insights. J Allergy Clin Immunol. 2026;9:100061.","journal-title":"J Allergy Clin Immunol."},{"issue":"11","key":"1818_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067268","volume":"12","author":"M Tringale","year":"2022","unstructured":"Tringale M, Stephen G, Boylan AM, Heneghan C. Integrating patient values and preferences in healthcare: A systematic review of qualitative evidence. BMJ Open. 2022;12(11):e067268.","journal-title":"BMJ Open."},{"issue":"4","key":"1818_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13555-025-01365-7","volume":"15","author":"G Ghezzi","year":"2025","unstructured":"Ghezzi G, Falcidia C, Paolino G, Mercuri SR, Narcisi A, Costanzo A, et\u00a0al. Chronic hand eczema (CHE): A narrative review. Dermatol Ther (Heidelb). 2025;15(4):771\u201395.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"1818_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40257-024-00890-z","volume":"25","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E. Chronic hand eczema. Am J Clin Dermatol. 2024;25(6):909\u201326.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01818-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:50Z","timestamp":1787243390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01818-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"April W. Armstrong has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO, UCB, Janssen, Lilly, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Regeneron, and Pfizer. Aseel Bin Sawad, Sanjeev Balu, and Douglas Maslin are employees of LEO Pharma, Inc. Nisha C. Hazra, B\u00e9a Libchaber, Rui Huang, Marjolaine Gauthier-Loiselle, and Annie Guerin are employees of Analysis Group ULC\/Inc. and have received consulting fees from LEO Pharma, Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is exempt by the Western Copernicus Group Institutional Review Board under 45 CFR \u00a7 46.104(d)(2) because the research only includes interactions involving educational tests, survey procedures, interview procedures, or observations of public behavior; the information obtained is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained, directly or through identifiers linked to the subjects. Informed consent was obtained from the participants prior to the start of the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}